Paliperidone palmitate once-monthly is an atypical long-acting injection to treat schizophrenia and is now approved in more than 80 countries, while the drug is marketed as Xeplion in
BTA585 is an orally bioavailable compound being developed to treat respiratory syncytial virus (RSV) infections in children, the elderly and immunocompromised patients. The Phase I SAD trial has
A six-month review period has been assigned for the sBLA and the Prescription Drug User Fee Act (PDUFA) date is expected to be in the first quarter of
Plitidepsin is an investigational anticancer agent of marine origin, originally obtained from the ascidian Aplidium albicans. As part of the deal, PharmaMar will receive an upfront payment, royalties
Axalimogene filolisbac is Advaxis’s investigational Lm Technology immunotherapy, while durvalumab is MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor. Around 66 patients will be included in the two-part, open-label Phase
The approval was based on data from the randomized, double-blind, multi-center Phase II BOLT study in patients with laBCC not amenable to local therapy or metastatic basal cell
TLRs are said to be important class of proteins that play a crucial role in the innate immune system and scientific evidence links aberrant TLR activation and signaling
Ibrance is an oral, first-in-class inhibitor of cyclin-dependent kinases (CDKs) 4 and 6, which are key regulators of the cell cycle that trigger cellular progression. With the validation
VL-2397 (ASP2397) is part of a potential new class of antifungal compounds for the treatment of systemic fungal infections, which are major causes of morbidity and mortality in
The first patient dosed is suffering from advanced adrenal cell carcinoma (ACC) and received a siRNA that blocks cell division. The company is focused on developing its proprietary
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.